DHX37 could affect the prognosis of patients with HCC or lung adenocarcinoma by immune infiltration, and can be used as a prognostic biomarker for HCC and lung adenocarcinoma (Xu et al., 2020; Chen et al., 2022). Here, DHX37 is linked to lung adenocarcinoma.